Tehran University of Medical Sciences Immunology and Genetics Journal 2645-4831 5 2 2022 06 22 69 76 Mahsima Shabani 1International Hematology/Oncology of Pediatrics Experts (IHOPE), Universal Scientific Education and Research Network (USERN), Tehran, Iran 2Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran Hanieh Mojtahedi 3Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran Maryam Sadr 3Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran Arezou Rezaei 3Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran Parivash Afradiasbagharani 3Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran Golshid Sanati 4Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran Zahra Aryan 2Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran 5Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran Farzad Kompani 6Division of Hematology and Oncology, Children's Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran Nima Rezaei Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; 4 Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran 2023 02 27 2023 02 27 Background: Acute Lymphoid Leukemia (ALL) is the leading childhood cancer with a high mortality and morbidity. Studies have suggested an association of epigenetic transformations with prognosis, recurrence and immunophenotypes of ALL. SOCS1 and SOCS3 are tumor suppressors inhibiting JAK/STAT signaling pathway and the resultant aberrant cell proliferation. Method: We aimed to assess the association between methylation status and ALL, using bone marrow and peripheral blood samples. 18 patients with ALL and 13 children with no malignancies were included. Using Bisulfite conversion, quantitative multiplex methylation-specific PCR and 2 -∆∆Ct formula, the methylated DNA in the promoters of SOCS1 and SOCS3 were measured. Results: ALL patients had higher mean methylation in SOCS1 promoter and lower mean methylation in SOCS3 promoter, compared to the control group. However, neither of these mean differences were statistically significant. Conclusion: This finding can set the foundation for further large-sample studies with the use of healthy children as a control group to strengthen the hypothetical association of the methylation status of SOCS1 and SOCS3 with ALL. https://igj.tums.ac.ir/index.php/igj/article/view/124 https://igj.tums.ac.ir/index.php/igj/article/download/124/102